Library · Metabolic & weight · Obesity and fatty liver disease treatment
Pemvidutide (ALT-801)
ALT-801, Pemvidutide, ALT801
An early-2020s dual GLP-1/glucagon receptor agonist (ALT-801) engineered for an extended half-life, aimed at obesity and fatty liver disease. Phase 2 data show encouraging reductions in liver fat, weight, and glucose markers.
Research score 85/100. Reference only, not a dose.
- Fat Loss
- Appetite Suppression
- Liver Protection
- Metabolic Enhancement
- GLP-1 Agonist
- US status
- Investigational
- Approval
- Phase 2 Clinical Trial
- Evidence
- Investigational GLP-1/Glucagon dual agonist. Shows robust weight loss and significant reduction in liver fat (MASH).
- Research score
- 85 / 100
- Indication
- Investigational - NASH/NAFLD
- Origin
- USA
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 activation raises insulin release and appetite suppression while cutting glucagon; simultaneous glucagon-receptor activation raises energy expenditure and liver fat oxidation; a linker technology sustains receptor engagement.
Safety file
Nausea and vomiting are the most common effects, generally mild to moderate and dose-related; no notable rise in heart rate or major cardiac events seen in trials.
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Decreased appetite